Publications by authors named "Colleen Dorsey"
Purpose: Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for patients who had been treated with ibrutinib in the front-line or relapsed/refractory settings with detectable MRD. Umbralisib and ublituximab (U2) were added on to ibrutinib, patients were treated until achieving undetectable-MRD (U-MRD), and then they entered a period of treatment-free observation (TFO).
View Article and Find Full Text PDFArticle Synopsis
- Intolerance to previous kinase inhibitors is a major reason for discontinuation in patients with chronic lymphocytic leukemia (CLL), prompting the trial of umbralisib, a new and selective PI3Kδ/CK1ε inhibitor.
- A phase 2 trial involving 51 previously treated CLL patients, who were intolerant to other treatments, showed that umbralisib had a median progression-free survival (PFS) of 23.5 months while maintaining a better tolerance than earlier therapies.
- The study indicated that a significant portion of patients (58%) remained on umbralisib longer than their initial treatments despite some experiencing adverse events, confirming umbralisib's potential as a viable option for this intoler
Article Synopsis
- Venetoclax-based therapy is a standard treatment for chronic lymphocytic leukemia (CLL), but how to manage patients after stopping it is unclear.
- A study involving 326 patients who discontinued venetoclax explored their responses to different treatments, focusing on overall response rate and progression-free survival.
- Results indicated that BTK inhibitors were highly effective for patients who had not previously received them, while less effective for those who had, and PI3K inhibitors provided limited benefit, highlighting the importance of treatment history when selecting post-venetoclax therapies.
Article Synopsis
- * A study compared 321 patients across the U.S. and U.K., analyzing demographics, treatment responses, and survival outcomes for both treatment approaches.
- * Results showed similar overall response rates and no significant differences in progression-free or overall survival between VENmono and VENcombo, suggesting both treatments are equally effective, though further studies are necessary for confirmation.
Article Synopsis
- - The study investigated the occurrence of tumor lysis syndrome (TLS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax outside of clinical trials, involving 297 patients from various treatment centers.
- - Among the findings, only 2.7% of patients experienced clinical TLS and 5.7% had laboratory TLS, with major adverse events including neutropenia and thrombocytopenia being notable.
- - The results suggest a need for better TLS risk grading and prophylaxis adherence in routine practice, despite progression-free survival being unaffected by dose modifications in this patient group.
Article Synopsis
- Venetoclax is a BCL2 inhibitor used to treat chronic lymphocytic leukemia (CLL) patients with specific genetic mutations, showing effectiveness even after previous kinase inhibitor treatments.
- A study of 141 CLL patients revealed a 72% overall response rate to Venetoclax, with common side effects including neutropenia and thrombocytopenia, but many patients reached the maximum recommended dosage.
- Further research is needed to determine the best order for using newer CLL therapies, as many patients successfully transitioned to other treatments like ibrutinib after stopping Venetoclax.
Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis of chronic lymphocytic leukemia patients treated with ibrutinib either commercially or on clinical trials.
View Article and Find Full Text PDF